Tetrazyklische antidepressiva: Pharmakologisch-klinische aspekte und neuentwicklungen

Nervenheilkunde

Volumn 15, Issue 2, 1996, Pages 92-100

  Demling, J ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Mianserin; Mirtazapine; Org 4428; Piperazino azepines; Setiptiline; Tetracyclic antidepressants

Indexed keywords

AMITRIPTYLINE; MIANSERIN; MIRTAZAPINE; ORG 4428; TECIPTILINE; TETRACYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

DEPRESSION; HUMAN; LEUKOPENIA; REVIEW;

EID: 0029901432     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Adams PC, Robinson A, Reid MM et al. Blood dyscrasias and mianserin. Postgrad Med J 1983; 59: 31-3.
2. Adverse Drug Reactions Advisory Committee. Mianserin. A possible cause of neutropenia and agranulocytosis. Med J Aust 1980; 2: 673-4.
3. Baumann PA, Maitre L. Blockade of presynaptic α-receptors and of amine uptake in the rat brain by the antidepressant mianserine. Naunyn-Schmiedeberg's Arch Pharmacol 1977; 300: 31-7.
4. Begg EJ, Sharman JR, Kidd JE et al. Variability in the elimination of mianserin in the elderly. Br J Clin Pharmacol 1989; 77: 445-51.
5. Benkert O, Hippius H. Psychiatrische Pharmakotherapie. 5. Aufl. Berlin, Heidelberg, New York: Springer 1992.
6. Bjertnaes A, Block JM, Hafstad PE et al. A multicentre placebo-controlled trial comparing the efficacy of mianserin and chlordiazepoxide in general practice patients with primary anxiety. Acta Psych Scand 1982; 66: 199-207.
7. Bremner JD. A double-blind comparison of Org 3770, amitriptyline and placebo in major depression, im Druck.
8. Carman JS, Ahdieh H, Wyatt-Knowles E et al. A controlled study of mianserin in moderately to severely depressed outpatients. Psychopharmacol Bull 1991; 27: 135-8.
9. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J 1987; 295: 1021-4.
10. Chand S, Crome P, Dawling S. One hundred cases of acute intoxication with mianserin hydrochloride. Pharmacopsychiatry 1981; 14: 15-7.
11. Claghorn JL, Lesem MD. A double-blind placebo controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995; 34: 165-71.
12. Clink HM, Shaw WL. Mianserin-induced agranulocytosis. Br Med J 1982; 285: 437-8.
13. Clink HM. Mianserin and blood dyscrasias. Br J Clin Pharmacol 1983; 15: 2915-2935.
14. Coulter DM, Edwards IR. Mianserin and agranulocytosis in New Zealand. Lancet 1990; 336: 785-7.
15. Coulter DM. Mianserin and agranulocytosis. Lancet 1990; II: 1010.
16. Curson DA, Hale AS. Mianserin and agranulocytosis. Br Med J 1979; 1: 378-9.
17. Curtis AL, Valentino RJ. Acute and chronic effects of the atypical antidepressant, mianserine, on brain noradrenergic neurons. Psychopharmacology 1991; 103: 330-8.
18. 1A-mediated serotonergic neurotransmission. CNS Drugs 1995; 4 (suppl. 1): 29-38.
19. Demling J et al. Klinik der nicht-trizyklischen Antidepressiva. In: Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 3: Antidepressiva und Phasenprophylaktika. Riederer P, Laux G, Pöldinger W (Hrsg). Wien, New York: Springer 1993: 127-251.
20. 2-antagonists. Acta Psychiatr Scand 1985; 72 (Suppl. 320): 20-5.
21. de Vanna M, Kummer J, Agnoli A et al. Moclobemide compared with second-generation antidepressants in elderly people. Acta Psychiatr Scand 1990; 82 (Suppl. 320): 64-6.
22. de Wilde J, Mertens C, Fredricson Overø K, Høpfner Petersen HE. Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 1985: 72: 89-96.
23. Dugas M, Mouren MC, Halfon O, Moron P. Treatment of childhood and adolescent depression with mianserin. Acta Psychiatr Scand 1985; 72 (Suppl. 320): 48-53.
24. Dunbar GC, Naarala M, Hiltunen H. A double-blind group comparison of mianserin and clomipramine in the treatment of mildly depressed psychiatric out-patients. Acta Psychiatr Scand 1985; 72: suppl 230: 60-6.
25. Farmer RDT, Pinder RM. Why do fatal overdose rates vary between antidepressants? Acta Psychiatr Scand 1989; 80 (Suppl. 354): 25-35.
26. Feighner JP, Jacobs RS, Jackson RE et al. A double-blind comparative trial with mianserin and amitriptyline in outpatients with major depressive disorders. Br J Clin Pharmacol 1983; 15: 2275-2375.
27. Forgan-Smith J, Leslie P. Neutropenia and mianserin. Med J Australia 1985; 143: 398.
28. Green SDR, Kendall-Taylor P. Heart block in mianserin hydrochloride overdose. Br Med J 1977; 2: 1190.
29. Guy W, McEvoy JM, Ban TA et al. A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology. Pharmacotherapy 1983; 3: 45-51.
30. Haefeli WE, Schoenenberger RA, Scholer A. Recurrent ventricular fibrillation in mianserin intoxication. Br Med J 1991; 302: 415-6.
31. Hla KK, Boyd O. Mianserin and complete heart block. Human Toxicol 1987; 6: 401-2.
32. Hodel J, Trum JM. Ergebnisse einer Feld-studie an ambulanten und stationären Patienten mit einem neuen Antidepressivum. Schweiz Rundschau Med (PRAXIS) 1977; 66: 1085-92.
33. Hopman H. Mianserin, in out-patients with depressive illness, in dosage up to 130 mg daily. Curr Med Res Opin 1980; 6 (Suppl. 7): 107-14.
34. Inman WHW. Blood disorders and suicide in patients taking mianserin or amitriptylin. Lancet 1988; II: 90-2.
35. Jaskari MO, Ahlfors UG, Ginman L et al. Three double-blind comparative trials of mianserine (ORG GB 94) and amitriptyline in the treatment of depressive illness. Pharmacopsychiatry 1977; 10: 101-3.
36. Jaskari MO. Observations on mianserin in the treatment of obsessive neuroses. Curr. Med Res Opin 1980; 6 (Suppl. 7): 128-31.
37. Kamimura M, Aoba A, Yamaguchi N et al. The effect of age on plasma level of setiptiline maleate in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 1015-26.
38. Knudsen K, Heath A. Effects of self-poisoning with maprotiline. Br Med J 1984; 288: 601-3.
39. Kuniyoshi M, Nakamura J, Miura C, Inanaga K. Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 339-46.
40. Langemark M, Loldrup D, Bech P, Olesen J. Clomipramine and mianserin in the treatment of chronic tension headache. A double-blind, controlled study. Headache 1990; 30: 118-21.
41. Loldrup D, Langemark M, Hansen HJ et al. Clomipramine and mianserin in chronic idiopathic pain syndrome: Psychopharmacology 1989; 99: 1-7.
42. Leinonen E. Serum mianserin concentrations in psychiatric inpatients of different ages. Acta Psychiatr Scand 1991; 81: 278-82.
43. Leinonen E, Koponen H, Lepola U. Serum mianserin and ageing. Prog Neuro-Psychopharmacol & Biol Psychiat 1994; 18: 833-45.
44. Manna V, Bolino F, Di Cicco L. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache 1994; 34: 44-9.
45. Marttila M, Jääskeläinen J, Järvi R et al. A double-blind study comparing the efficacy and tolerability of Org 3770 and doxepin in patients with major depression. Im Druck.
46. McGrath PJ, Rabkin JG, Stewart JW et al. Placebo-controlled study of mianserin in depressed outpatients. Neuropsychobiology 1985; 14: 128-32.
47. McHarg AM, McHarg JF. Leucopenia in association with mianserin treatment. Br Med J 1979; 1: 623.
48. Mendlewicz J, Dunbar GC, Hoffman C. Changes in sleep EEG architecture during the treatment of depressed patients with mianserin. Acta Psychiatr Scand 1985; 72: Suppl 320: 26-9.
49. Meredith TJ, Vale JA. Poisoning due to psychotropic agents. Adverse Drug React Acute Poisoning Rev 1985; 412: 83-126.
50. Mishra R, Janovsky A, Sulser F. Action of mianserin and zimelidine on the norepinephrine receptor coupled adenylate cyclase system in brain: subsensitivity without reduction in β-adrenergic receptor binding. Neuropharmacology 1980; 19: 983-7.
51. Mizuki Y, Kajimura N, Kai S et al. Effects of mianserin in chronic schizophrenia. Prog Neuro-Psychopharmacol & Biol Psychiat 1992; 16. 517-28.
52. Möller HJ, Meier K, Wernicke T. Empirical investigation on the risk of agranulocytosis/ leucopenia under medication with antidepressants. Pharmacopsychiatry 1988; 21: 304-5.
53. Monro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. Acta Psychiatr Scand 1985; 72: suppl 320: 98-103.
54. Montgomery SA. The effect of mianserin on sleep and cardiac function. Curr Med Res Opin 1980; 6: 23-8.
55. Montgomery SA, Baldwin D, Green M. Why do amitriptyline and dothiepin appear to be so dangerous in overdose? Acta Psychiatr Scand 1989; 80 (Suppl. 354): 47-53.
56. Montgomery SA, Bullock T, Pinder RM. The clinical profile of mianserin. Nord Psykiatr Tidsskr 1991; 45 (Suppl. 24): 27-35.
57. Morgan CA, Donaldson MD. Mianserin and agranulocytosis. Med J Australia 1986; 144: 165.
58. Murphy JE. Mianserin in the treatment of depressive illness and anxiety states in general practice. Br J Clin Pharmacol 1978; 5: 81S-82S.
59. Onghena P, De Cuyper H, Van Houdenhove B, Verstraeten D. Mianserin and chronic pain: a double-blind placebo-controlled process and outcome study. Acta Psychiatr Scand 1993; 88: 198-204.
60. Page CE. Mianserin-induced agranulocytosis. Br Med J 1982; 284: 1912-3.
61. Peet M, Behagel H. Mianserin: a decade of scientific development. Br J Clin Pharmacol 1978; 5: 5S-9S.
62. Perez A, Ashford JJ. A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. Curr Med Res Opin 1990; 12: 234-41.
63. Finder RM, van Delft AML. Pharmacological aspects of mianserin. Acta Psychiat Scand 1983; (Suppl. 302): 59-71.
64. Finder RM. Adrenoceptor interactions of the enantiomers and metabolites of mianserin: are they responsible for the antidepressant effect? Acta Psychiat Scand 1985; 72 (Suppl. 320): 1-9.
65. Finder RM. Mianserin. Pharmacological and clinical correlates. Nord Psykiatr Tidsskr 1991; 45: 13-26.
66. Finder RM, Wieringa JH. Third-generation antidepressants. Medic Res Rev 1993; 13: 259-325.
67. Proudfoot AT. Acute poisoning with antidepressants and lithium. Preservers' Journal 1986; 26: 97-106.
68. Richou H, Ruimy P, Charbaut J et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770 (im Druck).
69. Ruigt GSF, Kemp B, Groenhout CM et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990; 38: 551-4.
70. Ruigt GSF, de Boer T, Brockkamp C et al. Pharmacological profile of a new, highly selective noradrenaline reuptake blocker, Org 4428. Neuropharmacology, in Vorbereitung.
71. Saletu B, Grünberger J. Changes in clinical symptomatology and psychometric assessments in depressed patients during mianserin and combined amitriptyline/chlordiazepoxide therapy: a double blind comparison. Curr Med Res Opin 1980; 6 (Suppl. 7): 52-62.
72. Sindrup SH, Tuxen C, Gram LF et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251-5.
73. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms. Results from a placebo-controlled trial. Drug Invest 1994: 8: 339-44.
74. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs 1995; 4 (suppl. 1): 39-48.
75. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26: 191-6.
76. Tang SW, Seeman P. Effect of antidepressant drugs on serotonergic and adrenergic receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1984; 311: 255-61.
77. Tanum L. The effect of mianserin in chronic idiopathic abdominal pain. A pilot study. Nord J Psychiatry 1993; 47: 351-4.
78. Tiller J, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and mianserin in elderly depressed patients. Int J Geriatr Psychiatry 1990; 5: 199-204.
79. Väisänen E, Nummikko-Pelkonen A, Tienari P, Ranta P. Mianserin hydrochloride (Org GB-94) in the treatment of obsessional states. J Int Med Res 1977; 5: 289-91.
80. van der Burg WJ, Bonta IL, Delobelle J et al. A novel type of substituted piperazine with high antiserotonin potency. J Medicin Chem 1970; 1: 35-9.
81. van Houdenhove B, Verstraeten D, Onghena P, De Cuyper H. Chronic idiopathic pain, mianserin and "masked" depression. Psychother Psychosom 1992; 58: 46-53.
82. van Moffaert M, de Wilde J, Vereecken A et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10: 3-10.
83. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994; 4 (2): 145-50.
84. Vuori E, Ruohonen A, Penttilä A et al. Fatal poisonings with antidepressants in Finland 1985-1987. Acta Psychiatr Scand 1989; 80 (Suppl. 354): 55-60.
85. Wilcox CS, Cohn JB, Katz BB et al. A double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients. Int Clin Psychopharmacol 1994; 9: 271-9.
86. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol Clin Exp 1995; 10: 173-80.